Results of lithium- 131I treatment of thyrotoxicosis.
The role of lithium as an adjunct to 131I therapy of thyrotoxicosis has been assessed. Seventeen lithium- 131I treated patients and 16 control- 131I treated patients have been followed for almost three years. Five lithium- 131I and 3 control- 131I patients have become hypothyroid with the lithium treated patients developing earlier thyroid failure. Ten lithium and 10 control patients remain clinically and biochemically euthyroid. Two lithium- 131I and 2 control- 131I patients remain on low dose antithyroid drugs.
D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy*; D007454:Iodides / Q000627:therapeutic use*; D007457:Iodine Radioisotopes; D008094:Lithium / Q000627:therapeutic use*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D007454:Iodides; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D008094:Lithium; D013974:Thyroxine